Sage Therapeutics initiated with neutral view at Deutsche Bank, here’s why

Deutsche Bank initiated coverage of Sage Therapeutics with a Hold rating and $21 price target. There are multiple pipeline updates expected in 2024 which could drive upside to shares, the analyst tells investors in a research note. However, the firm says these readouts are all high risk.